查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1822373

2032 年治疗性神经毒素市场预测：按产品类型、配方、给药途径、技术、治疗用途、最终用户和地区进行的全球分析

Therapeutic Neurotoxin Market Forecasts to 2032 - Global Analysis By Product Type (Botulinum Toxin Type A and Botulinum Toxin Type B), Formulation, Administration Route, Technology, Therapeutic Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球治疗性神经毒素市场预计在 2025 年达到 64.7 亿美元，预计到 2032 年将达到 130.2 亿美元，预测期内的复合年增长率为 10.5%。

治疗性神经毒素，主要是肉毒桿菌毒素，是经过基因工程改造用于医疗用途的生技药品。肉毒桿菌毒素透过阻断特定肌肉的神经传导，从而控制肌肉放鬆并抑制过度活动。这些药物通常用于治疗偏头痛、肌张力不全症、痉挛和膀胱功能障碍等疾病。作为一种非手术治疗方法，神经毒素疗法已被证明安全有效。正在进行的研究正在进一步拓展神经毒素在治疗复杂神经和肌肉疾病方面的作用。

神经肌肉疾病盛行率上升

痉挛、慢性偏头痛和肌张力不全症等神经系统疾病的盛行率不断上升，推动了对治疗性神经毒素的需求。人口老化和诊断能力的提高，使得已开发经济体和新兴经济体的患者群体不断扩大。肉毒桿菌等神经毒素正被纳入个人化治疗通讯协定，以更有效地管理肌肉功能障碍。医院和专科诊所正在将这些治疗方法作为外科手术的非侵入性替代方案。标靶给药和缓释性製剂的创新正在改善治疗方法效果。随着认知度的提高，神经毒素正成为神经病学和復健多学科治疗的核心。

严格的监管核准流程

治疗性神经毒素因其强大的生物活性和复杂的生产要求而面临严格的监管审查。核准流程通常漫长，需要大量的临床试验和安全检验。 FDA 和 EMA 等监管机构要求提供严格的文件记录，尤其是针对新适应症和配方变更。先进的给药系统和数位监控工具的整合增加了合规性的复杂性。规模较小的生技公司往往难以应对监管成本和专家指导管道的有限性，减缓了创新。这些挑战可能会延迟产品上市，并限制某些地区的市场扩张。

神经毒素製剂的进展

研究人员正在开发长效且温度稳定的製剂，以提高患者用药便利性并减少给药频率。封装和标靶给药方面的创新正在提高精准度并最大限度地减少副作用。新兴趋势包括将神经毒素与佐剂结合以产生协同作用的混合製剂。监管机构越来越多地接受安全性和有效性更高的新型製剂。这些进展为扩大其在各种医疗环境中的适应症铺平了道路，包括疼痛管理和膀胱功能障碍。

替代治疗方法的可用性

副作用较少的非侵入性治疗正日益受到患者和医疗保健提供者的青睐。针对类似途径的生物製药和基因疗法正成为潜在的替代方案。此外，考虑到成本和报销限制，偏好可能会转向更经济实惠的治疗方案。神经调节和穿戴式装置的技术进步为肌肉疾病的治疗开闢了新的途径。如果没有持续的创新和临床检验，神经毒素可能会被这些不断发展的替代方案所掩盖。

COVID-19的影响

疫情扰乱了神经毒素供应链，推迟了择期手术，并影响了市场发展动能。封锁和重症加护监护资源的重新分配减少了患者获得治疗性注射的机会。然而，这场危机加速了数位医疗的普及，包括针对慢性神经系统疾病的远距会诊和远端患者监护。疫情后的復苏以重新关注分散式照护和门诊治疗模式为标誌。市场目前正在转向韧性、自动化和灵活的分销策略，以缓解未来的市场波动。

液体製剂市场预计将成为预测期内最大的市场

液体製剂因其易于给药且起效迅速，预计将在预测期内占据最大的市场份额。由于剂量稳定且製备要求低，这些製剂在临床环境中更受青睐。稳定性和保质期的技术改进正在提升其在全部区域的吸引力。液体神经毒素越来越多地用于门诊治疗，这与微创治疗的趋势相符。製造商正在投资包装创新，以支持低温运输物流并减少浪费。在对高效且可扩展解决方案的需求日益增长的背景下，液体製剂在治疗应用方面继续引领潮流。

预计专科诊所部门在预测期内的复合年增长率最高。

在集中式专业知识和以患者为中心的护理模式的推动下，专科诊所预计将在预测期内实现最高增长率。这些机构正迅速采用神经毒素治疗颈部肌张力不全症和眼睑痉挛等疾病。先进的影像学和肌电图引导注射技术的整合正在提高治疗精准度。诊所受益于简化的工作流程和更快的患者周转时间，从而提高了营运效率。新兴趋势包括行动神经毒素单元和数位化调度平台，以扩大可及性。随着医疗保健日益分散化，专科诊所在提供有针对性的神经毒素治疗方面变得至关重要。

比最大的地区

由于医疗保健投资不断增加以及神经系统疾病负担日益加重，预计亚太地区将在预测期内占据最大市场份额。中国、印度和韩国等国家正在透过公共卫生措施和不断发展的私营部门扩大神经毒素治疗的可及性。本地生产和有利的监管改革正在提高产品的可及性和可负担性。该地区肉毒桿菌毒素在治疗和美容领域的应用日益广泛。跨国公司与本地经销商之间的策略联盟正在加速市场渗透。

复合年增长率最高的地区：

在预测期内，北美预计将呈现最高的复合年增长率，这得益于其强大的开发平臺和创新神经毒素治疗方法的早期应用。美国和加拿大在探索扩大适应症和新型给药系统的临床试验方面处于领先地位。监管机构正在简化下一代製剂的核准流程，以促进更快的商业化。医院和专科诊所正在整合基于人工智慧的诊断和与电子病历 (EMR) 相关的治疗通讯协定，以优化神经毒素的使用。保险报销框架和医生培训计划正在推动神经毒素的广泛应用。

提供免费客製化：

此报告的订阅者可以使用以下免费自订选项之一：

  • 公司简介
    • 对最多三家其他市场公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 技术分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球治疗性神经毒素市场（依产品类型）

  • A型肉毒桿菌毒素
    • 肉毒桿菌
    • 杰沃
    • Dysport
    • Xeomin
  • B型肉毒桿菌
    • 肌阻断剂

6. 全球治疗性神经毒素市场（按配方）

  • 液体製剂
  • 冻干粉
  • 剂量强度
  • 组合产品和组合药物

7. 全球治疗性神经毒素市场（依给药途径）

  • 肌肉注射
  • 腺内注射
  • 皮内注射
  • 新型药物传输平台

8. 全球治疗性神经毒素市场（按技术）

  • 纯化的天然毒素
  • 人工神经毒素
  • 配方技术
  • 契约製造和CDMO

9. 全球治疗性神经毒素市场（依治疗应用）

  • 慢性偏头痛
  • 眼睑痉挛
  • 痉挛
  • 多汗症
  • 颈部肌张力不全症
  • 膀胱过动症
  • 颞颚关节障碍症

10. 全球治疗性神经毒素市场（依最终用户）

  • 医院
  • 专科诊所
  • 復健设施
  • 神经内科中心
  • 其他最终用户

11. 全球治疗性神经毒素市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十二章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章：企业概况

  • AbbVie Inc.
  • Lanzhou Institute of Biological Products Co., Ltd.
  • Ipsen Pharma
  • Shanghai Haohai Biological Technology Co., Ltd.
  • Revance Therapeutics, Inc.
  • Croma-Pharma GmbH
  • Medytox, Inc.
  • Allergan Aesthetics
  • Hugel, Inc.
  • Toxogen Ltd.
  • Daewoong Pharmaceutical Co., Ltd.
  • Sino Biopharmaceutical Limited
  • Evolus, Inc.
  • US WorldMeds, LLC
  • Merz Pharmaceuticals GmbH
Product Code: SMRC31127

According to Stratistics MRC, the Global Therapeutic Neurotoxin Market is accounted for $6.47 billion in 2025 and is expected to reach $13.02 billion by 2032 growing at a CAGR of 10.5% during the forecast period. Therapeutic neurotoxins, mainly based on botulinum toxin, are biological agents designed for medical use. They act by interrupting nerve communication with specific muscles, leading to controlled relaxation and reduced over activity. These agents are commonly prescribed for disorders like migraines, dystonia, spasticity, and bladder dysfunction. Offering a non-surgical treatment approach, therapeutic neurotoxins ensure safety and effectiveness. Ongoing studies are further broadening their role in addressing complex neurological and muscular health conditions.

Market Dynamics:

Driver:

Rising prevalence of neurological and muscular disorders

The increasing incidence of neurological conditions such as spasticity, chronic migraines, and dystonia is fuelling demand for therapeutic neurotoxins. Aging populations and improved diagnostic capabilities are expanding the patient pool across both developed and emerging economies. Neurotoxins like botulinum toxin are being integrated into personalized treatment protocols to manage muscular dysfunctions more effectively. Hospitals and specialty clinics are adopting these therapies as non-invasive alternatives to surgical interventions. Technological innovations in targeted delivery and sustained-release formulations are enhancing therapeutic outcomes. As awareness grows, neurotoxins are becoming central to multidisciplinary approaches in neurology and rehabilitation.

Restraint:

Strict regulatory approval processes

Therapeutic neurotoxins face stringent regulatory scrutiny due to their potent biological activity and complex manufacturing requirements. Approval pathways are often prolonged, requiring extensive clinical trials and safety validations. Regulatory bodies such as the FDA and EMA demand rigorous documentation, especially for new indications and formulation changes. The integration of advanced delivery systems and digital monitoring tools adds layers of complexity to compliance. Smaller biotech firms often struggle with regulatory costs and limited access to expert guidance, slowing innovation. These challenges can delay product launches and restrict market expansion in certain regions.

Opportunity:

Advancements in neurotoxin formulations

Researchers are developing long-acting variants and temperature-stable formulations to improve patient convenience and reduce dosing frequency. Innovations in encapsulation and targeted delivery are enhancing precision and minimizing side effects. Emerging trends include hybrid formulations combining neurotoxins with adjunctive agents for synergistic effects. Regulatory agencies are increasingly receptive to novel formulations that demonstrate improved safety and efficacy. These advancements are opening doors for expanded indications, including pain management and bladder dysfunction, across diverse healthcare settings.

Threat:

Availability of alternative treatment options

Non-invasive treatments with fewer side effects are gaining traction among patients and providers. Biologics and gene therapies targeting similar pathways are emerging as potential substitutes. Cost considerations and reimbursement limitations may also shift preference toward more affordable options. Technological progress in neuromodulation and wearable devices is offering new avenues for managing muscular disorders. Without continuous innovation and clinical validation, neurotoxins risk losing ground to these evolving alternatives.

Covid-19 Impact

The pandemic disrupted neurotoxin supply chains and delayed elective procedures, impacting market momentum. Lockdowns and resource reallocation toward critical care reduced patient access to therapeutic injections. However, the crisis accelerated digital health adoption, including teleconsultations and remote patient monitoring for chronic neurological conditions. Post-pandemic recovery is marked by renewed focus on decentralized care and outpatient treatment models. The market is now pivoting toward resilience, automation, and flexible distribution strategies to mitigate future disruptions.

The liquid formulations segment is expected to be the largest during the forecast period

The liquid formulations segment is expected to account for the largest market share during the forecast period, due to its ease of administration and rapid onset of action. These formulations are preferred in clinical settings for their consistent dosing and minimal preparation requirements. Technological improvements in stability and shelf-life are enhancing their appeal across geographies. Liquid neurotoxins are increasingly used in outpatient procedures, aligning with trends in minimally invasive care. Manufacturers are investing in packaging innovations to support cold-chain logistics and reduce wastage. As demand rises for efficient and scalable solutions, liquid formulations continue to lead in therapeutic adoption.

The specialty clinics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the specialty clinics segment is predicted to witness the highest growth rate, driven by their focused expertise and patient-centric care models. These facilities are rapidly adopting neurotoxin therapies for conditions like cervical dystonia and blepharospasm. Integration of advanced imaging and EMG-guided injection techniques is improving treatment precision. Clinics benefit from streamlined workflows and shorter patient turnaround times, enhancing operational efficiency. Emerging trends include mobile neurotoxin units and digital scheduling platforms to expand access. As healthcare decentralizes, specialty clinics are becoming pivotal in delivering targeted neurotoxin interventions.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share supported by rising healthcare investments and growing neurological disease burden. Countries like China, India, and South Korea are expanding access to neurotoxin therapies through public health initiatives and private sector growth. Local manufacturing and favorable regulatory reforms are boosting product availability and affordability. The region is witnessing increased adoption of botulinum toxin for both therapeutic and aesthetic applications. Strategic collaborations between global players and regional distributors are accelerating market penetration.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, driven by strong R&D pipelines and early adoption of innovative neurotoxin therapies. The U.S. and Canada are at the forefront of clinical trials exploring expanded indications and novel delivery systems. Regulatory agencies are streamlining approval processes for next-gen formulations, encouraging rapid commercialization. Hospitals and specialty clinics are integrating AI-based diagnostics and EMR-linked treatment protocols to optimize neurotoxin use. Reimbursement frameworks and physician training programs are supporting widespread adoption.

Key players in the market

Some of the key players profiled in the Therapeutic Neurotoxin Market include AbbVie Inc., Lanzhou Institute of Biological Products Co., Ltd., Ipsen Pharma, Shanghai Haohai Biological Technology Co., Ltd., Revance Therapeutics, Inc., Croma-Pharma GmbH, Medytox, Inc., Allergan Aesthetics, Hugel, Inc., Toxogen Ltd., Daewoong Pharmaceutical Co., Ltd., Sino Biopharmaceutical Limited, Evolus, Inc., US WorldMeds, LLC, and Merz Pharmaceuticals GmbH.

Key Developments:

In August 2025, AbbVie and Gilgamesh Pharmaceuticals Inc. announced a definitive agreement under which AbbVie will acquire Gilgamesh's lead investigational candidate, currently in clinical development for the treatment of patients with moderate-to-severe major depressive disorder (MDD).

In February 2021, Haohai Biological Technology announced that it acquired 63.64% shares in JUVA (Tianjin) Medical Technology Co., Ltd with a total investment of RMB 205 million Yuan, including JUVA's EndyMed RF skin equipment and instruments, Lasercon's VCSEL laser chips and equipment and Bioxis tissue filler and other main businesses and products into its medical aesthetics business portfolio.

Product Types Covered:

  • Botulinum Toxin Type A
  • Botulinum Toxin Type B

Formulations Covered:

  • Liquid Formulations
  • Lyophilized Powders
  • Dosage Strengths
  • Combination Products & Co-formulations

Administration Routes Covered:

  • Intramuscular Injection
  • Intraglandular Injection
  • Intradermal Injection
  • Novel Delivery Platforms

Technologies Covered:

  • Purified Native Toxins
  • Engineered Neurotoxins
  • Formulation Technologies
  • Contract Manufacturing & CDMOs

Therapeutic Applications Covered:

  • Chronic Migraine
  • Blepharospasm
  • Spasticity
  • Hyperhidrosis
  • Cervical Dystonia
  • Overactive Bladder
  • Temporomandibular Disorders

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Rehabilitation Facilities
  • Neurology Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Therapeutic Neurotoxin Market, By Product Type

  • 5.1 Introduction
  • 5.2 Botulinum Toxin Type A
    • 5.2.1 Botox
    • 5.2.2 Jeuveau
    • 5.2.3 Dysport
    • 5.2.4 Xeomin
  • 5.3 Botulinum Toxin Type B
    • 5.3.1 Myobloc

6 Global Therapeutic Neurotoxin Market, By Formulation

  • 6.1 Introduction
  • 6.2 Liquid Formulations
  • 6.3 Lyophilized Powders
  • 6.4 Dosage Strengths
  • 6.5 Combination Products & Co-formulations

7 Global Therapeutic Neurotoxin Market, By Administration Route

  • 7.1 Introduction
  • 7.2 Intramuscular Injection
  • 7.3 Intraglandular Injection
  • 7.4 Intradermal Injection
  • 7.5 Novel Delivery Platforms

8 Global Therapeutic Neurotoxin Market, By Technology

  • 8.1 Introduction
  • 8.2 Purified Native Toxins
  • 8.3 Engineered Neurotoxins
  • 8.4 Formulation Technologies
  • 8.5 Contract Manufacturing & CDMOs

9 Global Therapeutic Neurotoxin Market, By Therapeutic Application

  • 9.1 Introduction
  • 9.2 Chronic Migraine
  • 9.3 Blepharospasm
  • 9.4 Spasticity
  • 9.5 Hyperhidrosis
  • 9.6 Cervical Dystonia
  • 9.7 Overactive Bladder
  • 9.8 Temporomandibular Disorders

10 Global Therapeutic Neurotoxin Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Specialty Clinics
  • 10.4 Rehabilitation Facilities
  • 10.5 Neurology Centers
  • 10.6 Other End Users

11 Global Therapeutic Neurotoxin Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 AbbVie Inc.
  • 13.2 Lanzhou Institute of Biological Products Co., Ltd.
  • 13.3 Ipsen Pharma
  • 13.4 Shanghai Haohai Biological Technology Co., Ltd.
  • 13.5 Revance Therapeutics, Inc.
  • 13.6 Croma-Pharma GmbH
  • 13.7 Medytox, Inc.
  • 13.8 Allergan Aesthetics
  • 13.9 Hugel, Inc.
  • 13.10 Toxogen Ltd.
  • 13.11 Daewoong Pharmaceutical Co., Ltd.
  • 13.12 Sino Biopharmaceutical Limited
  • 13.13 Evolus, Inc.
  • 13.14 US WorldMeds, LLC
  • 13.15 Merz Pharmaceuticals GmbH

List of Tables

  • Table 1 Global Therapeutic Neurotoxin Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Therapeutic Neurotoxin Market Outlook, By Product Type (2024-2032) ($MN)
  • Table 3 Global Therapeutic Neurotoxin Market Outlook, By Botulinum Toxin Type A (2024-2032) ($MN)
  • Table 4 Global Therapeutic Neurotoxin Market Outlook, By Botox (2024-2032) ($MN)
  • Table 5 Global Therapeutic Neurotoxin Market Outlook, By Jeuveau (2024-2032) ($MN)
  • Table 6 Global Therapeutic Neurotoxin Market Outlook, By Dysport (2024-2032) ($MN)
  • Table 7 Global Therapeutic Neurotoxin Market Outlook, By Xeomin (2024-2032) ($MN)
  • Table 8 Global Therapeutic Neurotoxin Market Outlook, By Botulinum Toxin Type B (2024-2032) ($MN)
  • Table 9 Global Therapeutic Neurotoxin Market Outlook, By Myobloc (2024-2032) ($MN)
  • Table 10 Global Therapeutic Neurotoxin Market Outlook, By Formulation (2024-2032) ($MN)
  • Table 11 Global Therapeutic Neurotoxin Market Outlook, By Liquid Formulations (2024-2032) ($MN)
  • Table 12 Global Therapeutic Neurotoxin Market Outlook, By Lyophilized Powders (2024-2032) ($MN)
  • Table 13 Global Therapeutic Neurotoxin Market Outlook, By Dosage Strengths (2024-2032) ($MN)
  • Table 14 Global Therapeutic Neurotoxin Market Outlook, By Combination Products & Co-formulations (2024-2032) ($MN)
  • Table 15 Global Therapeutic Neurotoxin Market Outlook, By Administration Route (2024-2032) ($MN)
  • Table 16 Global Therapeutic Neurotoxin Market Outlook, By Intramuscular Injection (2024-2032) ($MN)
  • Table 17 Global Therapeutic Neurotoxin Market Outlook, By Intraglandular Injection (2024-2032) ($MN)
  • Table 18 Global Therapeutic Neurotoxin Market Outlook, By Intradermal Injection (2024-2032) ($MN)
  • Table 19 Global Therapeutic Neurotoxin Market Outlook, By Novel Delivery Platforms (2024-2032) ($MN)
  • Table 20 Global Therapeutic Neurotoxin Market Outlook, By Technology (2024-2032) ($MN)
  • Table 21 Global Therapeutic Neurotoxin Market Outlook, By Purified Native Toxins (2024-2032) ($MN)
  • Table 22 Global Therapeutic Neurotoxin Market Outlook, By Engineered Neurotoxins (2024-2032) ($MN)
  • Table 23 Global Therapeutic Neurotoxin Market Outlook, By Formulation Technologies (2024-2032) ($MN)
  • Table 24 Global Therapeutic Neurotoxin Market Outlook, By Contract Manufacturing & CDMOs (2024-2032) ($MN)
  • Table 25 Global Therapeutic Neurotoxin Market Outlook, By Therapeutic Application (2024-2032) ($MN)
  • Table 26 Global Therapeutic Neurotoxin Market Outlook, By Chronic Migraine (2024-2032) ($MN)
  • Table 27 Global Therapeutic Neurotoxin Market Outlook, By Blepharospasm (2024-2032) ($MN)
  • Table 28 Global Therapeutic Neurotoxin Market Outlook, By Spasticity (2024-2032) ($MN)
  • Table 29 Global Therapeutic Neurotoxin Market Outlook, By Hyperhidrosis (2024-2032) ($MN)
  • Table 30 Global Therapeutic Neurotoxin Market Outlook, By Cervical Dystonia (2024-2032) ($MN)
  • Table 31 Global Therapeutic Neurotoxin Market Outlook, By Overactive Bladder (2024-2032) ($MN)
  • Table 32 Global Therapeutic Neurotoxin Market Outlook, By Temporomandibular Disorders (2024-2032) ($MN)
  • Table 33 Global Therapeutic Neurotoxin Market Outlook, By End User (2024-2032) ($MN)
  • Table 34 Global Therapeutic Neurotoxin Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 35 Global Therapeutic Neurotoxin Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 36 Global Therapeutic Neurotoxin Market Outlook, By Rehabilitation Facilities (2024-2032) ($MN)
  • Table 37 Global Therapeutic Neurotoxin Market Outlook, By Neurology Centers (2024-2032) ($MN)
  • Table 38 Global Therapeutic Neurotoxin Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.